Cor­rect­ed: As­traZeneca, Dai­ichi Sankyo’s TROP2 ADC boosts sur­vival in Phase 3 lung can­cer sub­group

As­traZeneca and Dai­ichi Sankyo said their TROP2-di­rect­ed an­ti­body-drug con­ju­gate did not meet a pri­ma­ry sur­vival end­point in the over­all pop­u­la­tion of a late-stage lung can­cer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER